1. Patient and Clinician Perspectives on Preventive Therapy for Migraine

3. Global Burden of Migraine

4. Use of Preventive Migraine Medication in the United States: AMPP Study

5. Need for New Migraine Prevention Therapies

6. The Real-Life Patient: History

7. The Real-Life Patient: At Age 17

8. The Real-Life Patient: How Often Does She Experience Migraine Symptoms?

9. The Real-Life Patient: How Many Preventive Therapies Has She Tried Over the years?

10. The Real-Life Patient: How Has Migraine Affected Other Aspects of Your Life?

11. The Real-Life Patient: How Has Migraine Affected Your Work Life?

12. The Real-Life Patient: How Has Stigma Affected You?

13. The Nurse Practitioner Perspective: How Common Is Daily Migraine?

14. The Patient Advocate Perspective: What Are the Barriers?

15. American Migraine Foundation: Priorities and Initiatives

16. Patients Contributing to Research: Registries

17. Attitudes Toward New Treatments Among the Migraine Patient Community

18. Biologics: mAbs vs Small Molecules

19. Role of the Nurse Practitioner

20. Role of the Nurse Practitioner (cont)

21. Barriers to Effective Care

22. Patient Experience: Barriers to Effective Care

23. Anti-CGRP mAbs for Migraine Prevention: Efficacy and Safety Overview

24. Considerations for Treatment Choice

25. Patient Experience With First mAb

26. Experience With mAbs in Clinical Practice

27. Concluding Remarks

28. Concluding Remarks (cont)

29. Abbreviations